Physician profile
Ryan L Neff
NPI 1427245034
$3,395.20
in general payments reported to CMS, 2019-2025
40 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $84.17 · 2021: $131 · 2022: $491 · 2023: $393 · 2024: $695 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,147.04 | 2019-2025 | Phasix Mesh |
| Intuitive Surgical, INC. | $274.93 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $229.36 | 2019-2025 | Keytruda, Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $175.00 | 2021-2025 | Gattex |
| Allergan, INC. | $168.89 | 2019-2022 | |
| Tempus Ai, INC | $149.42 | 2024 | |
| W. L. Gore & Associates, INC. | $139.16 | 2019 | |
| Ethicon US, LLC | $130.04 | 2019-2022 | |
| Tela Bio, INC. | $107.57 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Abbott Laboratories | $90.98 | 2019 | |
| Kerecis Limited | $89.87 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Trevena, INC. | $74.94 | 2022 | |
| Polynovo North America LLC | $71.93 | 2024 | Novosorb Btm |
| Novartis Pharmaceuticals Corporation | $39.73 | 2019 | |
| Teleflex LLC | $36.47 | 2025 | Deflux Metal Needle |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.